You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

183 Results
Drug
Other Name(s): Bosulif®
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Zykadia™
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Zydelig™
Quick Link(s): Drug Monograph, Patient Info Sheet
Feb 2022
Drug
Other Name(s): Cotellic™
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Lenvima®
Quick Link(s): Drug Monograph, Patient Info Sheet
Sep 2023
Drug
Other Name(s): Ibrance™
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2025
Drug
Other Name(s): Venclexta®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2025
Drug
Other Name(s): Rydapt®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daSATinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SORAfenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2020

Pages